Rupal State

Medexus Announces Strongest Quarter in Company History with Fiscal Q2 2023 Revenue of US$27.7 Million, a 55% Increase Over Fiscal Q2 2022

Retrieved on: 
Tuesday, November 8, 2022
GLOBE, Rheumatoid arthritis, Meningioma, Aminolevulinic acid, Marketing, Investment, CDH, Calendar, Treosulfan, World Health Organization, Acceleration, MAT, Customer service, Webcast, Research, PAP, Glioma, Health Canada, Hematology, Mission statement, IQVIA, Hematopoietic stem cell transplantation, Safety, Allergy, EBITDA, Clinical trial, Patent, Patient, Growth, TSX, SEDAR, NDA, Blood, FDA, Pharmaceutical industry, Video game, Cryptocurrency, Risk management, Rupal State, Collaboration, Methotrexate

TORONTO and CHICAGO, Nov. 08, 2022 (GLOBE NEWSWIRE) --  Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company’s second fiscal quarter ended September 30, 2022. All dollar amounts in this press release are in United States dollars unless specified otherwise.

Key Points: 
  • Record total revenue of $27.7 million, a year-over-year increase of 55%, and a quarter-over-quarter increase of 20%.
  • This represents the strongest fiscal quarter in Medexuss history.
  • The primary drivers for this substantial year-over-year improvement were increases in revenues, a reduction in research & development costs, and an increase in gross margin.
  • Marcel Konrad, Chief Financial Officer of Medexus, further noted, During the second quarter we delivered an increase in our cash position versus previous quarter and generated positive operating cash flow this quarter.

Medexus Announces Record Fiscal Q1 2023 Revenue of US$23.0 Million, a 33% Increase versus Fiscal Q1 2022

Retrieved on: 
Monday, August 8, 2022
FDA, World Health Organization, Hematology, NDA, PAP, GLOBE, Treosulfan, Customer service, Growth, Investment, Methotrexate, TSX, Pharmacy, Research, MAT, IQVIA, Rheumatoid arthritis, Blood, Allergy, Marketing, Patient, Review, Calendar, Mission statement, Glioma, Health Canada, Hematopoietic stem cell transplantation, CDH, Webcast, Time, SEDAR, Video game, Pharmaceutical industry, Renewable energy, Aquaculture, Rupal State, Collaboration

TORONTO and CHICAGO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company’s first fiscal quarter ended June 30, 2022. All dollar amounts in this press release are in United States dollars unless specified otherwise.

Key Points: 
  • Delivered record total revenue of $23.0 million in fiscalQ12023, an increase of 33% compared to $17.3million in fiscalQ12022 and an increase of 13% compared to $20.3million in fiscalQ42022.
  • Achieved Adjusted EBITDA* of $1.9million in fiscalQ12023 compared to $(4.9)million in fiscalQ12022 and $1.1 million in fiscal Q4 2022.
  • Medexus achieved this Adjusted EBITDA increase while continuing to maintain appropriate investments in preparations for a commercial launch of treosulfan in the United States.
  • In addition, in August 2022, Medexus and medac signed an amendment to their February 2021 license agreement for treosulfan.

Medexus Pharmaceuticals Generated $21.3M in Fiscal 2022 Third Quarter Revenues and Achieved $1.9M Positive EBITDA for the Three Months Ended December 31, 2021

Retrieved on: 
Wednesday, February 9, 2022
GLOBE, NDA, Growth, Degenerative disease, Rupal State, Financial result, SEDAR, Operating cost, Income, Hematology, Three Months Gone, Telephone, Research, Company, Investment, Health Canada, Nine Months, Rheumatoid arthritis, Methotrexate, Risk, FDA, Medac, Patient, Review, Blood, MAT, EBITDA, Allergy, TSX, IQVIA, Rheumatology, Hematopoietic stem cell transplantation, Physician, Calendar, Mission statement, Customer service, MD, Video game, Renewable energy, Online gambling, Pharmaceutical industry, Medical device, Bookkeeping, Animal, Lithium, Cryptocurrency, Online shopping, Collaboration, Q3, Treosulfan

TORONTO and CHICAGO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP) (OTCQX: MEDXF) today announced its financial results and provided a business update for the three-month period ended December 31, 2021. All dollar amounts below are in United States dollars unless specified otherwise.

Key Points: 
  • Adjusted EBITDA* of $1.9 million, an increase from ($2.0) million in Q2 of fiscal 2022 and a decrease from $3.9 million in Q3 of fiscal 2021.
  • Cash and cash equivalents of $9.6 million (with $10.1 million of total available liquidity) at end of Q3 of fiscal 2022.
  • Ken dEntremont, Chief Executive Officer of Medexus, commented, We are encouraged to see sequential quarter-over-quarter growth in revenue and adjusted EBITDA this past quarter.
  • In particular, IXINITY saw improved sales in Q3 versus Q2 of fiscal 2022 aided by supply chain improvements.